GO
Loading...

Biotechnology

More

  • Ebola stocks: Who's leading?  Wednesday, 1 Oct 2014 | 2:21 PM ET

    Discussing which biotech companies working on treatments for deadly viruses are the most investable, with Dr. Neil Shahrestani, Pura Vida analyst.

  • GMO 'superseeds' leading to 'superweeds' Tuesday, 30 Sep 2014 | 11:22 AM ET

    The newest batch of crop seeds is setting off another debate over GMOs. This time, they're being blamed for an infestation of "superweeds."

  • Cramer: Stay on biotech  Wednesday, 24 Sep 2014 | 8:51 AM ET

    CNBC's Jim Cramer takes a look at what's putting pressure on the markets and why he is watching the biotech sector.

  • ImClone's Waksal plans IPO  Wednesday, 24 Sep 2014 | 7:31 AM ET

    CNBC's Meg Tirrell reports Sam Waksal is back in the biotechnology industry.

  • Tax crackdown impact on pharma deals  Tuesday, 23 Sep 2014 | 2:45 PM ET

    Discussing how the Treasury Department's new rules to end tax inversions could impact the pharma deals, with Michael Faerm, Wells Fargo Securities.

  • 3 Biotech picks: Gilead, Biogen & Celgene  Friday, 5 Sep 2014 | 12:54 PM ET

    Breaking down the hottest stocks in biotech now, with John Schroer, Allianz Global Investors.

  • Race for cholesterol drugs  Tuesday, 2 Sep 2014 | 8:17 AM ET

    A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known about bad cholesterol, and competition in the space.

  • Why US biotech stocks are back in favor  Monday, 25 Aug 2014 | 7:16 PM ET

    While biotechnology shares are not cheap, they are nowhere near "bubble-like" valuations, says Bill Stone, Chief Investment Strategist at PNC Asset Management Group.

  • Roche's blockbuster pharma deal  Monday, 25 Aug 2014 | 3:47 PM ET

    CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.

  • What Roche gets from InterMune  Monday, 25 Aug 2014 | 10:09 AM ET

    Switzerland's Roche is buying InterMune for $8.3 billion. CNBC's Meg Tirrell reports InterMune's Esbriet drug could draw more than $1 billion in annual revenue.

  • Roche's $8.3 billion deal for InterMune  Monday, 25 Aug 2014 | 9:06 AM ET

    Drug giant Roche is buying biotech firm InterMune for $8.3 billion. CNBC's Jim Cramer discusses the lifesaving drug behind the wave of M&A deals.

  • Big change for pain drugs  Friday, 22 Aug 2014 | 2:12 PM ET

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Aug 19- The U.S. government has extended a contract with Cytori Therapeutics to develop a cell-derived treatment for burns, the company said on Tuesday. The government's Biomedical Advanced Research and Development Authority will provide up to $20.4 million to fund early development and costs associated with a clinical trial.

  • Hot biotech drugs  Tuesday, 19 Aug 2014 | 7:07 AM ET

    CNBC's Meg Tirrell reports which biotech drug developments investors are excited about.

  • Fighting obesity with Rxs  Monday, 18 Aug 2014 | 2:17 PM ET

    Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.

  • Red hot biotech stocks  Thursday, 14 Aug 2014 | 3:10 PM ET

    CNBC's Morgan Brennan runs through today's big biotech movers.

  • Time to buy biotech?  Wednesday, 13 Aug 2014 | 4:38 PM ET

    Barbara Ryan, FTI Consulting, discusses the tremendous amount of innovation within in the biotech sector and why the segment is attractive.

  • Biotechs race for Ebola cure  Monday, 11 Aug 2014 | 5:30 PM ET

    CNBC's Meg Tirrell looks at companies in the early stages of Ebola drug and vaccine trials.

  • Merck & Pfizer beat the Street  Tuesday, 29 Jul 2014 | 10:14 AM ET

    CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

  • What's coming in biotech?  Wednesday, 23 Jul 2014 | 2:15 PM ET

    "The market is very favorable for biotech these days," says Les Funtleyder, Bluecloud Healthcare, in discussing growth in the space.